摘要
目的探讨那屈肝素在经皮冠状动脉介入治疗(PCI)中应用的有效性和安全性。方法将我院2005年5月至2006年1月收治的共172例行PCI术的患者分为2组。A组为PCI术中用那屈肝素(0.1 ml/10 kg),B组为PCI术中用普通肝素(133μkat,1μkat=60 u)。A组87(男62,女25)例,年龄(63±3)岁。B组85(男71,女14)例,年龄(62±2)岁。PCI前静脉注射那屈肝素或普通肝素。A组和B组又分别分为择期和急诊PCI。出血程度的判断根据TIMI研究的标准进行。观察所有患者的心脏事件(死亡、再梗死、血运重建)。结果两组的一般临床资料比较差异无显著性。A组与B组手术成功率(100%vs100%);30 d内主要心血管不良事件比较两组差异均无显著性;在轻微出血方面那屈肝素显著低于普通肝素组(P<0.05)。结论那屈肝素在急性心肌梗死患者行PCI术中的应用是有效的、安全的。
AIM To investigate the effectiveness and safety of using Natroparin in PCI. METHODS One hundred and seventy-two PCI patients, who were hospitalized from May 2005 to January 2006 in the Fourth Affiliated Hospital of Harbin Medical University, were randomly divided into two groups. Natroparin was used in group A （87 patients： 62 males and 25 females, average age 63 ±3） and common unfractionated heparin was used in group B （85 patients 71 ： males and 14 females, average age 62 ±2）. Before PCI, patients in group A were intravenously given Natroparin （ 0.1 ml/10 kg） while those in group B was intravenously given unfractionated heparin （133 μkat） for procedural anticoagulation. Bleeding complications were classified according to Thrombolysis in Myocardial Infarction （TIMI） criteria and the bleeding indexes （changes in hemoglobin） were calculated. All the patients were followed up for major adverse clinical events （MACE） such as death, myocardial infarction and need for revascularization for 30 days after PCI. RESULTS No significant difference was found in baseline characteristics between the two groups. The success rate of operation in both groups was 100% （ 100 % vs 100% ）. For the 30-day follow-up, there was no significant difference in MACE between the two groups but minor hemorrhage in Natroparin group was significantly lower than that in unfractionated heparin group. CONCLUSION The application of Natroparin in PCI is safe and effective.
出处
《心脏杂志》
CAS
2007年第1期53-56,共4页
Chinese Heart Journal
关键词
肝素
那屈肝素
经皮冠状动脉介入治疗
主要心脏事件
Heparin
natroparin
percutaneous coronary intervention
major adverse cardiac event
